Literature DB >> 6946464

Molecular lesion affecting the ADP-combining site in a mutant isozyme of erythrocyte pyruvate kinase.

D E Paglia, W N Valentine.   

Abstract

Erythrocyte pyruvate kinase (PK) from a patient with PK deficiency was characterized according to internationally standardized procedures. In addition to low activity, the mutant isozyme displayed impaired kinetics specifically affecting the ADP-combining site:Km (ADP) was 3-5 times greater than normal when determined at three different concentrations of phosphoenolpyruvate (P-enolpyruvate). Maximum reaction velocities were not achieved until ADP was 10 times the concentration normally required for control PK. Substrate inhibition by high concentrations of ADP and competitive inhibition by ATP were markedly diminished. Other nucleoside diphosphates normally capable of replacing ADP in the PK reaction were less effective with the mutant isozyme than with PK from controls or from subjects with other forms of PK deficiency, and Michaelis--Menten constants for several of these (UDP, GDP, CDP) were significantly elevated. Whereas all previously known PK kinetic defects have involved the substrate P-enolpyruvate, the half-saturation constant K0.5s (P-enolpyruvate) for this mutant isozyme was normal, as was its response to fructose-1,6-bisphosphate activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6946464      PMCID: PMC320363          DOI: 10.1073/pnas.78.8.5175

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Studies on erythrocyte glycolysis. I. Determination of the glycolytic intermediates in human erythrocytes.

Authors:  S Minakami; C Suzuki; T Saito; H Yoshikawa
Journal:  J Biochem       Date:  1965-12       Impact factor: 3.387

2.  Kinetic differences between human red cell and leucocyte pyruvate kinase.

Authors:  J O Campos; R D Koler; R H Bigley
Journal:  Nature       Date:  1965-10-09       Impact factor: 49.962

3.  Stabilization, partial purification, and effects of activating cations, ADP, and phosphoenolpyruvate on the reaction rates of an erythrocyte pyruvate kinase.

Authors:  K H Ibsen; K W Schiller; E A Venn-Watson
Journal:  Arch Biochem Biophys       Date:  1968-12       Impact factor: 4.013

4.  Evidence for molecular alteration of pyruvate kinase as a consequence of erythrocyte aging.

Authors:  D E Paglia; W N Valentine
Journal:  J Lab Clin Med       Date:  1970-08

5.  Human erythrocyte pyruvate kinase. Its purification and some properties.

Authors:  G E Staal; J F Koster; H Kamp; L van Milligen-Boersma; C Veeger
Journal:  Biochim Biophys Acta       Date:  1971-01-13

6.  Hereditary erythrocyte pyruvate kinase deficiency: molecular and functional studies of four mutant PK variants detected in Spain.

Authors:  J Marie; J L Vives-Corrons; A Kahn; B Kernemp
Journal:  Clin Chim Acta       Date:  1977-12-01       Impact factor: 3.786

7.  International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis.

Authors:  E Beutler; K G Blume; J C Kaplan; G W Löhr; B Ramot; W N Valentine
Journal:  Br J Haematol       Date:  1977-02       Impact factor: 6.998

Review 8.  Pyruvate kinase deficiency.

Authors:  K R Tanaka; D E Paglia
Journal:  Semin Hematol       Date:  1971-10       Impact factor: 3.851

9.  An inherited molecular lesion of erythrocyte pyruvate kinase. Identification of a kinetically aberrant isozyme associated with premature hemolysis.

Authors:  D E Paglia; W N Valentine; M A Baughan; D R Miller; C F Reed; O R McIntyre
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

10.  Human erythrocyte pyruvate kinase deficiency: the use of a kinetic study of mutant enzymes for the detection of heterozygotes.

Authors:  E D Sprengers; J Marie; A Kahn; K Punt; G E Staal
Journal:  Hum Genet       Date:  1978-02-23       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.